Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Breast cancer research and treatment - 1 May 2013

Rath Michelle G, Masciari Serena, Gelman Rebecca, Miron Alexander, Miron Penelope, Foley Kathleen, Richardson Andrea L, Krop Ian E, Verselis Sigitas J, Dillon Deborah A, Garber Judy E

Abstract excerpt

Breast cancer is the most frequent tumor in Li-Fraumeni syndrome (LFS), a rare inherited cancer syndrome associated with germline mutations in the TP53 gene. Recent data show that breast cancer in germline TP53 mutation carriers is commonly HER2+ (63-83 %). We assessed the prevalence of germline TP53 mutations in a cohort of women with HER2+ breast cancer diagnosed age ≤50 years. We identified blood specimens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prevalence
Share to Tumor Suppressor Protein p53

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to DNA Mutational Analysis

Share to Genes, erbB-2

Share to Germ-Line Mutation

Share to Li-Fraumeni Syndrome

Share to Multiplex Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 23580068
DOI: 10.1007/s10549-012-2375-z
PMCID: PMC4280061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of germline TP53 mutations in HER2+ breast cancer patients.PMID 23580068Read ↗

Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndromeSemantic proximity Read ↗

Early onset HER2-positive breast cancer is associated with germline TP53 mutations.Semantic proximity Read ↗

Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican populationSemantic proximity Read ↗

Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.Semantic proximity Read ↗

Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.Semantic proximity Read ↗

TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate.Semantic proximity Read ↗

Clinical implications of germline mutations in breast cancer: TP53.Semantic proximity Read ↗

TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohortSemantic proximity Read ↗

Germline TP53 pathogenic variants and breast cancer: A narrative review.Semantic proximity Read ↗

Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.Semantic proximity Read ↗

Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.Semantic proximity Read ↗

The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.